IB2 anticorps (AA 31-130) (FITC)

N° du produit ABIN1710091

Cet anticorps Lapin Polyclonal détecte spécifiquement IB2 dans WB, IF (cc) et IF (p). Il présente une réactivité envers Humain.

Aperçu rapide pour IB2 anticorps (AA 31-130) (FITC) (ABIN1710091)

Antigène: IB2 (JIP-2) (C-Jun-Amino-Terminal Kinase-Interacting Protein 2 (JIP-2))

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp IB2 est conjugé à/à la FITC

Application: Western Blotting (WB), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p))

Détail du produit anti-IB2 anticorps (FITC)

Épitope: AA 31-130

Homologie: Human,Mouse,Rat,Cow,Horse

Purification: Purified by Protein A.

Immunogène: KLH conjugated synthetic peptide derived from human JIP2

Isotype: IgG

Information d'application

Indications d'application: IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Date de péremption: 12 months

Détails sur IB2

Antigène: IB2 (JIP-2) (C-Jun-Amino-Terminal Kinase-Interacting Protein 2 (JIP-2))

Autre désignation: JIP2

Sujet:

Synonyms: MAPK8IP2, C jun amino terminal kinase interacting protein 2, C-jun-amino-terminal kinase-interacting protein 2, Homologous to mouse JIP 1, IB 2, IB-2, IB2, Islet brain 2, Islet-brain-2, JIP 2, JIP-2, JIP2, JIP2_HUMAN, JNK interacting protein 2, JNK MAP kinase scaffold protein 2, JNK MAP kinase scaffold protein JIP2, JNK-interacting protein 2, MAPK8IP2, Mitogen activated protein kinase 8 interacting protein 2, Mitogen-activated protein kinase 8-interacting protein 2, PRKM8 interacting protein like, PRKM8IPL.

Background: c-Jun NH2-terminal kinases (JNKs) are distant members of the MAP kinase family (1). JNK1 is activated by dual phosphorylation at a Thr-Pro-Tyr motif in response to ultraviolet (UV) light, and it functions to phosphorylate c-Jun at amino terminal serine regulatory sites, Ser-63 and Ser-73, resulting in transcriptional activation (2-5). Two additional JNK family members have been identified as JNK2 and JNK3 (3). JIP-1 (for JNK interacting protein-1) has been identified as a cytoplasmic inhibitor of JNK that retains JNK in the cytoplasm, thereby inhibiting JNK-regulated gene expression. Evidence suggests that JNK1 and JNK2 bind to JIP-1 with greater affinity than to ATF-2 and c-Jun, which are targets of the JNK signaling pathway. JIP-1 contains an amino terminal JNK binding domain and a carboxy terminal SH3 domain. ATF-2 and c-Jun also contain the JNK binding domain and are thought to compete with JIP-1 for JNK binding (6). Multiple splice variants if JIP-1, including JIP-1b, JIP-1c (also designated islet-brain 1 or IB-1), JIP-2a, JIP-2b and JIP-3, have been identified in brain (7).